Loading organizations...
Key people at Korify Capital.
Korify Capital operates as a venture capital firm, investing in biotechnology companies focused on longevity, mental health, and chronic disease prevention. Their investment methodology targets distributed development companies, enabling technologies, and specialized domain-specific platforms. This approach transforms healthcare delivery and outcomes, mitigating biotech investment risks.
Founded in 2020 by Robin Lauber and co-founder Davide Ottolini, Korify Capital emerged from a conviction in biotechnology’s profound impact. Lauber, who established the family office Infinitas Capital, recognized accelerating interest in health innovation, particularly influenced by the global pandemic. The founders saw healthcare shifting towards proactive maintenance and disease prevention.
Korify Capital partners with visionary companies developing solutions to prevent illness and enhance quality of life, targeting startups with potential to extend human healthspan. Their long-term vision supports breakthrough technologies, enabling individuals to live longer, healthier, and more fulfilled lives through preventative healthcare advancements.
Key people at Korify Capital.
Korify Capital is a Basel, Switzerland–based investment firm specializing in early and growth-stage biotech ventures, with a strong focus on longevity, mental health, and regenerative medicine. Its mission is to back breakthrough technologies that extend healthy lifespan and address mental health challenges by investing in companies that have demonstrated strong traction and proof of concept, primarily in Series A to C funding rounds. Korify’s portfolio includes innovative firms like Alto Neuroscience, which uses AI to develop psychiatric treatments, and Cambrian Biopharma, focused on therapeutics to lengthen healthspan. The firm leverages deep biotech expertise and a broad venture capital network to support transformative startups that aim to redefine healthcare and improve quality of life[1][2][3].
Founded by Robin and Peter Lauber’s family office, Infinitas Capital, Korify Capital has evolved to emphasize three core investment strategies: distributed development companies, enabling technologies, and domain-specific platforms. These strategies allow the firm to invest in scalable, target-agnostic platforms with multiple uncorrelated approaches to common goals, reducing binary risk typical in biotech. Korify’s approach balances broad applicability and strong domain expertise, making its portfolio attractive for business development and M&A activity. The firm’s focus on longevity and mental health aligns with growing global trends toward preventive healthcare and improved quality of life[1][3][4].
Korify Capital rides the wave of increasing interest in longevity and mental health biotech, sectors poised for disruption due to advances in AI, genomics, and regenerative medicine. The timing is critical as global populations age and mental health challenges rise, creating urgent demand for innovative therapies. Korify’s investments contribute to transforming healthcare from reactive disease treatment to proactive health maintenance and lifespan extension, influencing the biotech ecosystem by fostering companies that blend cutting-edge science with scalable business models[1][3].
Looking ahead, Korify Capital is positioned to capitalize on accelerating biotech innovations in longevity and mental health, sectors expected to grow substantially in the coming decade. Its focus on enabling technologies and platform companies suggests a strategy to diversify risk and maximize impact. As the firm continues to back visionary teams and breakthrough science, its influence in shaping the future of healthcare—particularly in extending healthy lifespan and improving mental wellness—is likely to expand, reinforcing its role as a key player in the biotech investment landscape[1][3].
Korify Capital has 9 tracked investments across 7 companies. The latest tracked deal is $6.0M Seed in Azuro in October 2025.
